Devices & Diagnostics, Pharma, Startups

Personalized medicine player Theranostics has new CEO, raising $1M

Personalized medicine player Theranostics is in the midst of a modest fund raise – it’s raising […]

Personalized medicine player Theranostics is in the midst of a modest fund raise – it’s raising $1 million in equity, according to a regulatory filing.

Not to be confused with biotech media darling Theranos – the Bay Area startup that means to do a wide range of testing form a single blood drop – Theranostics still wades in the same paddling pool: The Philadelphia company develops ways to measure the activation of signaling pathways necessary in molecular targeted therapies and companion diagnostics. The companies are so-named because of their sector, theranostics – the confluence of therapeutics and diagnostics.

This funding announcement comes on the heels of Theranostics’ Oct. 27 appointment of Luis T. Gutierrez as its president and CEO. Gutierrez is moving over from a VP stint at clinical research org Aptiv Solutions.

More from MedCity News on Theranostics here.

Shares0
Shares0